Dyne Therapeutics Announces New Clinical Data from ACHIEVE T

- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - - DYNE-101 Showed Improvement in Myotonia,...

Related Keywords

United States , Stacy Nartker , Wildon Farwell , Amy Reilly , John Cox , Exchange Commission , Nasdaq , Drug Administration , Facebook , Linkedin , Myotonic Dystrophy Health Index , European Medicines Agency , Dyne Therapeutics Inc , Dose Dependent , Mean Splicing Correction Across All Patients , Muscle Strength , Timed Function Tests , Reported Outcomes , Mean Unadjusted , Mean Muscle Adjusted , Dystrophin Expression , Cohort Administered Monthly , Higher Level , Dystrophin Than Reported , Weekly Administered Standard , Functional Improvement , Run Time , Stride Velocity , Safety Profiles , Enrollment Complete , Recent Regulatory Interactions , Pursue Expedited Approvals , Both Programs , Registrational Pathways Expected , Investor Event Today , Timed Assessments , Quantitative Myometry Testing , Run Test , Dystrophy Health Index , Dystrophy Type , Participation Scale , North Star Ambulatory Assessment , Drug Evaluation , Myotonic Dystrophy Type , Duchenne Muscular Dystrophy , Private Securities Litigation Reform Act , Clinical Update ,